HRS 2012 UPDATE: Riata’s survival rate ‘significantly worse’ May 10, 2012 By Brad Perriello Leave a Comment A study comparing recalled defibrillator leads made by St. Jude Medical (NYSE:STJ) with 1 from rival Medtronic (NYSE:MDT) found 1 St. Jude model’s survival rate to be "significantly worse."